April 14, 2021
AABB SmartBrief
News for the transfusion medicine and biotherapies communitySIGN UP ⋅   SHARE
ADVERTISEMENT
Top Story
More than 192 million doses of COVID-19 vaccine had been administered in the US as of Tuesday, with 75.3 million people now fully vaccinated, the CDC reports. After US health agencies recommended that use of a vaccine made by Johnson & Johnson be paused after six reported incidents of blood clotting after vaccination, White House COVID-19 coordinator Jeff Zients said the country has "more than enough supply" of vaccines made by Pfizer/BioNTech and Moderna to maintain the current pace of vaccination.
Full Story: Reuters (4/13),  Reuters (4/13) 
LinkedIn Twitter Facebook Email
You're more than a hero. You're a superhero.
This year, blood bankers have risen to meet enormous challenges. In the face of a strained blood supply, support of convalescent plasma therapy, and countless logistical hurdles, you persevered in the name of patient care. Thank you for your unfailing commitment to this life-saving work. Happy Medical Lab Professionals Week 2021!
ADVERTISEMENT:
Science & Health
The NIH has been sponsoring research on an effective, easy-to-use antiviral drug for COVID-19, but developing antivirals requires identifying molecular vulnerabilities in a virus, screening hundreds of thousands of compounds that target the vulnerabilities, testing promising compounds in laboratories and then testing the best candidates -- if any -- in animals before starting clinical trials. Merck and partner Ridgeback Biotherapeutics; Atea Pharmaceuticals; and Pfizer have reached the clinical trial phase.
Full Story: STAT (tiered subscription model) (4/9),  MyNorthwest (Seattle) (4/13) 
LinkedIn Twitter Facebook Email
Emerging Trends
Moderna on Tuesday announced that, based on results from a six-month follow-up of participants in a Phase 3 trial, its COVID-19 vaccine continues to provide strong protection against the virus six months after the second dose was given, with efficacy against all types of COVID-19 cases at more than 90% and more than 95% against severe COVID-19. The company is also working on versions of the vaccine that target the variant B.1.351.
Full Story: Reuters (4/13) 
LinkedIn Twitter Facebook Email
Industry News & Practice
Eli Lilly and Co. announced it revised a contract with the US government for bamlanivimab, the drugmaker's COVID-19 antibody drug, due to concerns about its efficacy against new coronavirus variants. The modified agreement states the drug will now be sold in combination with etesevimab and cancels the remaining orders of bamlanivimab scheduled for delivery by the end of March.
Full Story: Reuters (4/12) 
LinkedIn Twitter Facebook Email
Antios Therapeutics, a startup working on a cure for hepatitis B, raised $96 million in its most recent funding round. With the new capital the company will continue its research, and CEO Greg Mayes said the company will be prepared for an initial public offering.
Full Story: Endpoints News (free registration) (4/13) 
LinkedIn Twitter Facebook Email
Government & Regulatory
The Senate Finance Committee is set to hold a confirmation hearing Thursday for Chiquita Brooks-LaSure, the Biden administration's nominee for CMS administrator. Brooks-LaSure previously worked in the HHS Branch at the White House Office of Management and Budget, was on staff at the House Ways and Committee and was at the CMS' Center for Consumer Information and Insurance Oversight.
Full Story: ThinkAdvisor (free registration) (4/12) 
LinkedIn Twitter Facebook Email
The White House is running public service announcements on "The Deadliest Catch" and partnering with Country Music Television and NASCAR to reach Americans who are skeptical about getting a COVID-19 vaccine, according to White House press secretary Jen Psaki. About 30% of Republicans and white evangelical Christians say they won't get a COVID-19 vaccine, according to a Kaiser Health News poll.
Full Story: CNBC (4/12) 
LinkedIn Twitter Facebook Email
Emergency use authorization was granted to Thermo Fisher Scientific's high-throughput version of its Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit. The kit may help labs flag SARS-CoV-2 variants.
Full Story: 360Dx (tiered subscription model) (4/13) 
LinkedIn Twitter Facebook Email
Association News
The 10th edition of Standards for Cellular Therapy Services (CT Standards) is now available for purchase in both electronic and printed formats. The 10th edition will take effect July 1 and includes several changes and additions, including standards to address bacterial contamination risk, data breaches, vulnerable donor populations, novel infectious diseases and data reporting. A print version of the CT Standards and Guidance bundle is also available for pre-order. Additional information is available in the AABB Store.
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
JOBS
  Executive Director of Quality/Regulatory Affairs
COMMUNITY BLOOD CENTER/COMMUNITY TISSUE SERVICES - Kettering, OH, US
View More Listings | Post a Job
Sharing AABB SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/aabb/?referrerId=eSriBJbAIQ
Judge not for your flaws, but for your Triumphs!
Whitney Houston,
singer, actor
LinkedIn Twitter Facebook Email
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004